Securities code: 002082 securities abbreviation: Wanbangde Pharmaceutical Holding Group Co.Ltd(002082) Announcement No.: 2022-001 Wanbangde Pharmaceutical Holding Group Co.Ltd(002082)
Announcement on full receipt of equity transfer payment for sale of major assets
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Overview of major asset sales
Wanbangde Pharmaceutical Holding Group Co.Ltd(002082) (hereinafter referred to as “listed company” or “company”) held the fifth meeting of the eighth board of directors and the fifth meeting of the eighth board of supervisors on December 23, 2020, the sixth meeting of the eighth board of directors and the sixth meeting of the eighth board of supervisors on January 10, 2021, and the first extraordinary general meeting of shareholders in 2021 on January 26, 2021, The proposal on the company’s major asset restructuring plan and other relevant proposals were reviewed and approved, and the company was agreed to sell 100% equity of Dongliang Aluminum Co., Ltd. (hereinafter referred to as “Dongliang aluminum”) and 51% equity of Huzhou Jiacheng metal coating Co., Ltd. (hereinafter referred to as “Huzhou Jiacheng”) to Huzhou Wanbangde Pharmaceutical Holding Group Co.Ltd(002082) Investment Co., Ltd. (hereinafter referred to as “Huzhou Jiacheng investment”), Wanbangde Pharmaceutical Holding Group Co.Ltd(002082) the investment was purchased in cash, with a total transaction amount of 1.351 billion yuan. For details, please refer to the company’s disclosure on cninfo.com on December 24, 2020, January 11, 2021 and January 27, 2021（ http://www.cn.info.com..cn. ）Relevant announcements.
Before February 26, 2021, the listed company has received 51.07% of the consideration for this transaction. The company completed the industrial and commercial change registration procedures for 100% equity of Dongliang aluminum and 51% equity of Huzhou plus on March 1, 2021. For details, see the announcement on the completion of the transfer of the subject assets of major asset sales and related party transactions disclosed on March 3, 2021 (Announcement No.: 2021-019).
2、 Completion and payment of equity transfer
Before February 26, 2021, the counterparty Wanbangde Pharmaceutical Holding Group Co.Ltd(002082) investment has paid a total of 690 million yuan to the listed company.
According to the agreement on sale of major assets, the counterparty’s Wanbangde Pharmaceutical Holding Group Co.Ltd(002082) investment shall timely and fully pay the remaining total amount of RMB 661 million within 12 months after the agreement on sale of major assets takes effect. As of December 31, 2021, Wanbangde Pharmaceutical Holding Group Co.Ltd(002082) investment has paid a total of 661 million yuan to the listed company in advance.
As of the disclosure date of this announcement, the company has received the transaction price of 1.351 billion yuan for the sale of major assets in full. Through this transaction, the company fully improves the cash flow situation, optimizes the capital structure of the listed company, provides financial support for the company’s new drug R & D and drug production technology improvement projects, and enhances the listed company’s anti risk ability and sustainable operation ability.
It is hereby announced.
Wanbangde Pharmaceutical Holding Group Co.Ltd(002082)
Board of directors
January 4, 2002
